Whereas our results suggest that combining NK cell-based immunotherapeutic approaches with strategies aimed at targeting MYC might be inappropriate, data by others suggest that targeting MYC in lymphoma cells exerts beneficial effects on NK cell responses (Swaminathan et al, 2020). The gene discussed is MYC; the disease is lymphoma.